MEN’S HEALTH QUARTERLY
Longevity

Sermorelin Side Effects: What the Studies Report and What Is Unknown

Most sermorelin safety data come from children and small adult trials. Here is what each source found.

Words by the editors ·

In the published studies, the most common sermorelin side effects were brief facial flushing and pain where the injection went in.1 Those findings come mostly from children, and long-term data in healthy adult men are thin: a 2018 review of growth hormone secretagogues found them generally well tolerated in the studies available, with some concern about higher blood glucose, and said long-term safety, including cancer incidence, still needs study.3 Below is what each source actually reports, and what it leaves out.

In brief

  • The most commonly reported sermorelin side effects were transient facial flushing and pain at the injection site, in a review of children with growth hormone deficiency.1
  • In a 5-month placebo-controlled trial of a closely related GHRH analog in 19 people aged 55 to 71, transient hyperlipidemia was the only adverse side effect.2
  • A review of growth hormone secretagogues found them generally well tolerated but flagged higher blood glucose and the need for long-term safety data, including cancer incidence.3
  • Adults today receive compounded sermorelin, which the FDA says is not FDA-approved.4,5

What side effects have studies reported?

EffectWhere it was reportedLimits
Transient facial flushing, pain at the injection siteA review of sermorelin in children with growth hormone deficiency called these the most commonly reported adverse events, with single intravenous and repeated daily subcutaneous doses well tolerated1Children, not adult men; dosed by body weight for a diagnosis or growth1
Transient rise in blood fats (hyperlipidemia)A 5-month placebo-controlled trial of nightly injections of a closely related 29 amino acid GHRH analog in 9 men and 10 women aged 55 to 71 reported this as the only adverse side effect, and it resolved by the end of the study219 people; an analog, not sermorelin itself; the same trial found thicker skin in both sexes2
Higher blood glucoseThe secretagogue review flagged concern for increases in blood glucose from decreased insulin sensitivity3Fasting glucose and insulin were unchanged in the 19-person trial, so findings are mixed2
Prolactin and cortisol changes, fluid retention, joint and muscle painA 2026 endocrinology review of GH-axis peptides, including sermorelin, lists these across the class6Narrative review of mixed products, many sold as unregulated "research compounds"6

What are the side effects of sermorelin in men?

The short answer: no study has measured sermorelin side effects in healthy adult men on a long-term, controlled basis, so the list comes from children and small trials in older adults. The most commonly reported effects are brief facial flushing and pain at the injection site.1 Reported or flagged possibilities in adults include a temporary rise in blood fats with a related analog2 and higher blood glucose through reduced insulin sensitivity.3

One reason reviewers describe these peptides as generally well tolerated is how they act: growth hormone secretagogues prompt the body's own pulsatile growth hormone release, which stays subject to negative feedback, unlike injected growth hormone.3 That is a design argument, not proof of safety. The same review says few long-term, rigorously controlled studies exist.3

Is sermorelin safe?

Short answer: short-term use looked well tolerated in the studies that exist, but safety over years in healthy adult men has not been established. The sermorelin review in children reported mainly transient flushing and injection-site pain,1 and the secretagogue review called these peptides generally well tolerated while flagging blood glucose and the need for long-term data.3 Because adults today receive a compounded product that the FDA says has not been reviewed for safety and effectiveness,5 "safe" depends on the pharmacy, the dose and the person's own health, which is why a prescriber should review it first.

What are the side effects of the sermorelin peptide?

Sermorelin is a growth hormone releasing hormone analog, so its effects sit in the same family as other growth hormone secretagogue peptides. The documented ones are flushing and injection-site pain with sermorelin itself,1 a temporary rise in blood fats with a related analog,2 and, across the peptide class, prolactin and cortisol changes, fluid retention and joint or muscle pain.6 Those class-wide effects come from a narrative review of mixed products, so they are not all shown for sermorelin specifically.6

What are the long-term side effects of sermorelin?

None have been established, because no long-term controlled study in healthy adult men exists. The secretagogue review says few long-term, rigorously controlled studies are available and that cancer incidence and mortality need further study.3 The longest trial cited above ran 5 months in 19 people using a related analog.2 Absence of long-term reports here means absence of data, not a clean record.

Do the children's findings apply to adults?

Only loosely. The sermorelin review that reports flushing and injection-site pain covers children with idiopathic growth hormone deficiency, treated with bedtime subcutaneous doses set by body weight.1 An adult man taking compounded sermorelin for energy or sleep is a different person, dose and goal, so the absence of serious events in that review is not a guarantee for him.

Are there long-term risks?

Nobody can say yet. The secretagogue review states that few long-term, rigorously controlled studies exist and that the long-term impact on the body, including cancer incidence and mortality, needs further work.3 The 2026 review calls the concern that these peptides could promote tissue growth biologically plausible but unproven.6 Both are statements of uncertainty, not evidence that sermorelin causes cancer. A man with a past cancer, a pituitary or thyroid condition, or diabetes is the person who most needs to raise it with a prescriber first.

Is sermorelin safe if it is compounded?

A DailyMed search on October 20, 2026 listed no sermorelin label, so adults who use it today receive a compounded product.4 The FDA says compounded drugs are not FDA-approved and have not been reviewed for safety and effectiveness.5 That is different from the label-level safety data an approved drug carries, such as a full list of adverse reactions from large trials. It also matters where the product comes from: the 2026 review warns about uncertain composition and dosing in unregulated supply chains.6

The FDA also keeps a list of bulk drug substances for compounding that may present significant safety risks. On the page as we loaded it, the list names ipamorelin acetate and CJC-1295, two other peptides often sold alongside sermorelin, but we did not find sermorelin on it.7 Not being listed is not an endorsement. It means the agency has not published that particular warning about it.

Who should be most careful?

What should a man ask before starting?

For the benefit side of the ledger, see whether the evidence supports the benefits men are sold, and for how it compares with a similar peptide, sermorelin vs ipamorelin. The basics are in our explainer on this peptide.

Bottom line

The documented side effects are mild and short-lived, mostly flushing and injection-site pain, with possible effects on blood fats and glucose. The honest limit is that the data are old, small or from children, and nothing long-term is known for healthy adult men. That uncertainty, plus compounding, is the real safety question.

Talk to a clinician. This article explains the evidence; it cannot tell you what is right for you. A licensed clinician who knows your health history and medications can.
Important safety information. NAD+ and sermorelin are prescription injections. Compounded versions are not FDA-approved.5 Tell the prescribing clinician about every medication and supplement you take, and about any history of cancer, pituitary or thyroid conditions, or pregnancy. Only a licensed clinician who knows your health history should decide whether a prescription is appropriate for you.

Questions

What are the most common side effects of sermorelin?

In a review of children treated with sermorelin, transient facial flushing and pain at the injection site were the most commonly reported adverse events.

Does sermorelin raise blood sugar?

A review of growth hormone secretagogues flagged concern for increased blood glucose from decreased insulin sensitivity. A small 19-person trial of a related analog saw no change in fasting glucose, so results are mixed.

Is sermorelin safe long term?

Unknown. Reviews say few long-term, rigorously controlled studies exist, and that cancer incidence and mortality need further study.

Is compounded sermorelin FDA-approved?

No. A DailyMed search on October 20, 2026 listed no sermorelin label, and the FDA states compounded drugs are not FDA-approved.

Do sermorelin side effects in men differ from children?

Almost no controlled data exist in healthy adult men. The reported flushing and injection-site pain come from a review of children, and adult findings come from small trials of a related analog.

Does sermorelin cause cancer?

Not shown. Reviews say cancer incidence and mortality with growth hormone secretagogues still need study, which is a statement of uncertainty, not evidence of harm.

Is sermorelin safe?

Short-term use was generally well tolerated in the studies that exist, mostly in children, but long-term safety in healthy adult men has not been established and adults receive a compounded product the FDA has not reviewed.

Also in this edition

Part of our guide: Sermorelin: The Complete Guide

Notes

  1. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. PubMed 18031173.
  2. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997. PubMed 9141536.
  3. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018. PubMed 28400207.
  4. Sermorelin search. DailyMed, U.S. National Library of Medicine. Searched October 20, 2026.
  5. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
  6. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol. 2026. PubMed 42395176.
  7. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed October 20, 2026.